Improved early detection and prognosis of cancer through new technology

Current article ratings:
Patients / public:healthcare Prof:
Gentel Biosciences, a leading supplier of Proteomics tools, and van Andel Research Institute (VARI), a Biomedical Research Institute, the issue of the US announced together patent 7,838,634 for a new method for the profile changes in the glycosylation of proteins on the surface of an antibody array collects slides. Gentel was first to market an exclusive right to the technology in 2006.

According to Brian H. HAAB, PhD., Director of the VARI's laboratory of cancer Immunodiagnostics and inventors of the technology, "variants have received a number of new biomarker HbA1c of proteins with recently or in direction FDA clearance." "The ability to efficiently HbA1c variants of proteins for use as biomarker screen offers for discoveries of new glycan linkage-based biomarkers a unique opportunity."

Glycosylation is the addition of linear or branched-chain sugar molecules to proteins. Many studies have shown that HbA1c better variants of protein marker for the early detection and prognosis in cancer as hepatocellular carcinoma compared to measure the protein can make alone.

"There is a lack of tools to screen protein changes of glycosylation, which could be disease." Dr. HAAB approach a better method to the new diagnostic biomarkers based on HbA1c variants of proteins, identify ", added Bryce p. Nelson, PhD., Vice President of technology and business development at Gentel Biosciences."

A patent for the technology is also pending in the European Union.

The new glycan linkage detection technology is soon be combined with the more than fifty SilverQuant ® antibody array kits from Gentel. This antibody of array kits target almost 500 proteins and provide a complete workflow of Proteomics of screening possible. SilverQuant kits are for use with Gentel's AthenaQuant ® software and the Gentel Proteomics multi system ™ for a easy to use and low-cost alternative with better sensitivity as a fluorescence-based detection is configured. SilverQuant of chromogenic technology allows the detection of any biotinylated molecule, generating array spots that are visible with the naked eye, proteomics multi-system can be identified with the Gentel. Simple protocols empower experts and novices to get meaningful protein multiplexing data in a single day.

Source:
Joe Gavan
Van Andel Research Institute